CN100384846C - 稠合吡咯-嘧啶衍生物 - Google Patents

稠合吡咯-嘧啶衍生物 Download PDF

Info

Publication number: CN100384846C
Authority: CN; China
Prior art keywords: alkyl; amino; optional; replaces; expression
Prior art date: 2002-09-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CNB038233673A

Other languages

English (en)

Chinese (zh)

Other versions

CN1688582A (zh

Inventor

M·施马达

T·穆拉塔

K·富基卡米

H·楚吉施塔

N·奥莫里

I·卡托

M·缪拉

K·乌尔巴恩斯

F·甘特纳

K·巴康

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Pharma AG

Bayer Intellectual Property GmbH

Original Assignee

Bayer Pharmaceuticals Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-30

Filing date

2003-09-18

Publication date

2008-04-30

2003-09-18 Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp

2005-10-26 Publication of CN1688582A publication Critical patent/CN1688582A/zh

2008-04-30 Application granted granted Critical

2008-04-30 Publication of CN100384846C publication Critical patent/CN100384846C/zh

2023-09-18 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

CNB038233673A 2002-09-30 2003-09-18 稠合吡咯-嘧啶衍生物 Expired - Lifetime CN100384846C (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02021861		2002-09-30
EP02021861.6		2002-09-30

Publications (2)

Publication Number	Publication Date
CN1688582A CN1688582A (zh)	2005-10-26
CN100384846C true CN100384846C (zh)	2008-04-30

Family

ID=32039115

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CNB038233673A Expired - Lifetime CN100384846C (zh)	2002-09-30	2003-09-18	稠合吡咯-嘧啶衍生物

Country Status (33)

Country	Link
US (2)	US7511041B2 (und)
EP (2)	EP1549652B1 (und)
JP (1)	JP4790266B2 (und)
KR (1)	KR101059652B1 (und)
CN (1)	CN100384846C (und)
AR (2)	AR041426A1 (und)
AT (2)	ATE511510T1 (und)
AU (1)	AU2003293310B2 (und)
BR (1)	BRPI0314830B8 (und)
CA (1)	CA2499134C (und)
CY (2)	CY1109790T1 (und)
DE (1)	DE60324296D1 (und)
DK (2)	DK1549652T3 (und)
EC (2)	ECSP055768A (und)
ES (2)	ES2367141T3 (und)
HK (1)	HK1084393A1 (und)
HR (2)	HRP20050375B1 (und)
IL (1)	IL166855A (und)
MA (1)	MA27483A1 (und)
MX (1)	MXPA05001808A (und)
MY (1)	MY140756A (und)
NO (1)	NO331457B1 (und)
NZ (1)	NZ539062A (und)
PE (1)	PE20050089A1 (und)
PL (1)	PL226562B1 (und)
PT (2)	PT2042504E (und)
RU (1)	RU2326881C9 (und)
SI (2)	SI1549652T1 (und)
TW (1)	TWI327570B (und)
UA (1)	UA82205C2 (und)
UY (1)	UY28001A1 (und)
WO (1)	WO2004029055A1 (und)
ZA (1)	ZA200503306B (und)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6667300B2 (en)	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
CN102718665B (zh)	2003-08-29	2015-09-16	三井化学株式会社	农园艺用杀虫剂的制备中间体
SI2612862T1 (sl)	2004-05-13	2017-04-26	Icos Corporation	Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
EP2343303A1 (de)	2004-10-07	2011-07-13	Boehringer Ingelheim International GmbH	PI3-Kinase Inhibitoren
WO2006040645A1 (en) *	2004-10-11	2006-04-20	Ranbaxy Laboratories Limited	N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
EP2390347A1 (en)	2005-04-14	2011-11-30	Trustees Of Boston University	Diagnostic for lung disorders using class prediction
CA2617225A1 (en) *	2005-07-29	2007-02-15	4Sc Ag	Novel heterocyclic nf-kb inhibitors
US7517995B2 (en) *	2006-04-06	2009-04-14	Boehringer Ingelheim International Gmbh	Thiazolyl-dihydro-cyclopentapyrazole
US7691868B2 (en)	2006-04-06	2010-04-06	Boehringer Ingelheim International Gmbh	Thiazolyl-dihydro-quinazoline
PT2041139E (pt) *	2006-04-26	2012-01-13	Hoffmann La Roche	Compostos farmacêuticos
WO2008064244A2 (en) *	2006-11-20	2008-05-29	The Trustees Of Columbia University In The City Of New York	Phosphoinositide modulation for the treatment of neurodegenerative diseases
AR064106A1 (es) *	2006-12-05	2009-03-11	Bayer Schering Pharma Ag	Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP1953163A1 (en) *	2007-02-01	2008-08-06	Boehringer Ingelheim Pharma GmbH & Co. KG	Pteridinone derivatives as PI3-kinases inhibitors
WO2008148023A2 (en) *	2007-05-23	2008-12-04	Medical College Of Georgia Research Institute, Inc.	Compositions and methods for treating neurological disorders
WO2009039140A1 (en) *	2007-09-17	2009-03-26	Smithkline Beecham Corporation	Pyridopyrimidine derivatives as pi3 kinase inhibitors
US20090186951A1 (en)	2007-09-19	2009-07-23	Brody Jerome S	Identification of novel pathways for drug development for lung disease
CA2713388C (en) *	2008-01-14	2016-03-29	William Scott	Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2009094224A1 (en)	2008-01-25	2009-07-30	Millennium Pharmaceuticals, Inc.	Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
US20090227575A1 (en) *	2008-03-04	2009-09-10	Wyeth	7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
EP2277881A4 (en) *	2008-04-18	2011-09-07	Shionogi & Co	HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K
EP2303890A4 (en) *	2008-06-19	2012-04-11	Progenics Pharm Inc	INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE
EP2168583A1 (en)	2008-09-24	2010-03-31	Bayer Schering Pharma Aktiengesellschaft	Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2168582A1 (en)	2008-09-24	2010-03-31	Bayer Schering Pharma Aktiengesellschaft	Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
ES2614130T3 (es) *	2008-09-30	2017-05-29	Pfizer Inc.	Compuestos de imidazo[1,5]naftiridina, su uso farmacéutico y composiciones
MX2011004957A (es) *	2008-11-11	2011-08-12	Je Il Pharmaceutical Co Ltd	Nuevo derivado triciclico o las sales farmaceuticamente aceptables del mismo, metodo de preparacion del mismo, y composicion farmaceutica que contiene el mismo.
ES2674719T3 (es)	2008-11-13	2018-07-03	Gilead Calistoga Llc	Terapias para neoplasias hematológicas
US9492449B2 (en)	2008-11-13	2016-11-15	Gilead Calistoga Llc	Therapies for hematologic malignancies
US9495515B1 (en)	2009-12-09	2016-11-15	Veracyte, Inc.	Algorithms for disease diagnostics
US9139589B2 (en)	2009-01-30	2015-09-22	Millennium Pharmaceuticals, Inc.	Heteroaryls and uses thereof
US9090601B2 (en)	2009-01-30	2015-07-28	Millennium Pharmaceuticals, Inc.	Thiazole derivatives
US8440677B2 (en)	2009-03-24	2013-05-14	Gilead Calistoga Llc	Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
JP2012524126A (ja)	2009-04-20	2012-10-11	ギリアドカリストガリミテッドライアビリティカンパニー	固形腫瘍の治療方法
AU2010243613B2 (en) *	2009-04-30	2015-05-07	Glaxo Group Limited	Oxazole substituted indazoles as PI3-kinase inhibitors
KR20120049281A (ko)	2009-07-21	2012-05-16	길리아드 칼리스토가 엘엘씨	Ｐｉ３ｋ 억제제를 이용한 간 장애의 치료
TWI499592B (zh) *	2009-09-09	2015-09-11	Avila Therapeutics Inc	Ｐｉ３激酶抑制劑及其用途
PE20130191A1 (es) *	2010-04-16	2013-02-21	Bayer Ip Gmbh	Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida
US9062038B2 (en)	2010-08-11	2015-06-23	Millennium Pharmaceuticals, Inc.	Heteroaryls and uses thereof
MX2013003695A (es)	2010-10-01	2013-05-20	Bayer Ip Gmbh	Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida.
WO2012062743A1 (en) *	2010-11-11	2012-05-18	Bayer Pharma Aktiengesellschaft	Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
CN103339133B (zh) *	2010-11-11	2016-06-15	拜耳知识产权有限责任公司	烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉
UA113280C2 (xx) *	2010-11-11	2017-01-10		АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
EP2508525A1 (en)	2011-04-05	2012-10-10	Bayer Pharma Aktiengesellschaft	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar)	2011-04-05	2021-01-31	Bayer Ip Gmbh	استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
US8865730B2 (en)	2012-03-05	2014-10-21	Gilead Calistoga Llc	Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
WO2014186036A1 (en)	2013-03-14	2014-11-20	Allegro Diagnostics Corp.	Methods for evaluating copd status
KR20150130451A (ko)	2013-03-15	2015-11-23	제넨테크, 인크.	암 치료 방법 및 항암제 내성 예방을 위한 방법
CU24400B1 (es)	2013-04-08	2019-04-04	Bayer Pharma AG	Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
EA029568B8 (ru)	2013-05-01	2018-08-31	Ф.Хоффманн-Ля Рош Аг	Бигетероарильные соединения и их применения
WO2015027431A1 (en)	2013-08-29	2015-03-05	Merck Sharp & Dohme Corp.	2,2-difluorodioxolo a2a receptor antagonists
WO2015095601A1 (en)	2013-12-20	2015-06-25	Gilead Calistoga Llc	Process methods for phosphatidylinositol 3-kinase inhibitors
JP2017500319A (ja)	2013-12-20	2017-01-05	ギリアードカリストガエルエルシー	（ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
CA2952012A1 (en)	2014-06-13	2015-12-17	Gilead Sciences, Inc.	Phosphatidylinositol 3-kinase inhibitors
CN114606309A (zh)	2014-11-05	2022-06-10	威拉赛特公司	使用机器学习和高维转录数据的诊断系统和方法
EP3018131A1 (en)	2014-11-07	2016-05-11	Bayer Pharma Aktiengesellschaft	Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en)	2014-11-07	2016-05-11	Bayer Pharma Aktiengesellschaft	Synthesis of copanlisib and its dihydrochloride salt
BR112017019188A2 (pt)	2015-03-09	2018-04-24	Bayer Pharma Aktiengesellschaft	Combinações contendo 2,3-di-hidroimidazo[1,2-c] quinazolina substituídas
CN105130997B (zh) *	2015-09-25	2017-12-05	苏州明锐医药科技有限公司	一种库潘尼西的制备方法
CN105130998B (zh) *	2015-09-25	2017-07-28	苏州立新制药有限公司	库潘尼西的制备方法
CA3016584A1 (en)	2016-03-08	2017-09-14	Bayer Pharma Aktiengesellschaft	2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
EP3219329A1 (en)	2016-03-17	2017-09-20	Bayer Pharma Aktiengesellschaft	Combinations of copanlisib
US10927417B2 (en)	2016-07-08	2021-02-23	Trustees Of Boston University	Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
CA3037626A1 (en)	2016-09-23	2018-03-29	Bayer Pharma Aktiengesellschaft	Combination of pi3k-inhibitors
JP2020503289A (ja)	2016-12-14	2020-01-30	ターベダセラピューティクスインコーポレイテッドＴａｒｖｅｄａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	Ｈｓｐ９０標的化コンジュゲート及びその製剤
EP3585437B1 (en)	2017-02-24	2022-12-21	Bayer Pharma Aktiengesellschaft	Combinations of copanlisib with anti-pd-1 antibody
WO2019002068A1 (en)	2017-06-28	2019-01-03	Bayer Consumer Care Ag	COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST
EP3498266A1 (en)	2017-12-15	2019-06-19	Bayer Consumer Care AG	Formulations of copanlisib
DK3678644T3 (da)	2017-09-08	2023-07-31	Bayer Pharma AG	Formuleringer af copanlisib
CN111247152A (zh) *	2017-09-20	2020-06-05	璧辰医药技术股份有限公司	作为激酶抑制剂的环状亚氨基嘧啶衍生物
US11351156B2 (en)	2017-10-13	2022-06-07	Inserm	Combination treatment of pancreatic cancer
EP3713963A1 (en)	2017-11-23	2020-09-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	A new marker for predicting the sensitivity to pi3k inhibitors
WO2019105734A1 (en)	2017-11-28	2019-06-06	Bayer Consumer Care Ag	Combinations of copanlisib
WO2019105835A1 (en)	2017-11-29	2019-06-06	Bayer Consumer Care Ag	Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en)	2018-04-11	2019-10-17	Bayer Aktiengesellschaft	Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
WO2020020385A1 (zh) *	2018-07-27	2020-01-30	上海翰森生物医药科技有限公司	含三并环类衍生物抑制剂、其制备方法和应用
CN109053554B (zh) *	2018-08-01	2020-07-28	江苏八巨药业有限公司	一种使用催化剂合成3-乙酰吡啶的方法
WO2020043617A1 (en)	2018-08-28	2020-03-05	Bayer As	Combination of pi3k-inhibitors and targeted thorium conjugates
US20210369724A1 (en)	2018-10-16	2021-12-02	Bayer Aktiengesellschaft	Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
WO2020096927A1 (en)	2018-11-05	2020-05-14	Iovance Biotherapeutics, Inc.	Expansion of tils utilizing akt pathway inhibitors
US20220040324A1 (en)	2018-12-21	2022-02-10	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugate and kinase inhibitor
WO2020164997A1 (en)	2019-02-12	2020-08-20	Bayer Aktiengesellschaft	Combination of pi3k-inhibitors
CN114621236A (zh) *	2022-04-25	2022-06-14	河南湾流生物科技有限公司	一种喹啉类饲料添加剂的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3644354A (en) *	1968-09-16	1972-02-22	Sandoz Ag	5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
CN1089266A (zh) *	1993-01-02	1994-07-13	陈基旺	3-取代甲基-2，3-二氢咪唑并[1，2-c]喹唑啉衍生物，其制备与用途
US5932584A (en) *	1997-05-06	1999-08-03	National Science Council	Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4287341A (en)	1979-11-01	1981-09-01	Pfizer Inc.	Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
EP0771204A4 (en)	1994-08-12	1999-10-20	Pro Neuron Inc	METHODS OF TREATING SEPSIA OR INFLAMMATORY DISEASES WITH OXYPURINE-BASED NUCLEOSIDES
AU709190B2 (en) *	1996-01-29	1999-08-26	United States Of America, Represented By The Secretary, Department Of Health And Human Services, The	Dihydropyridine-, pyridine-, benzopyran- one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
GEP20084317B (en)	2000-04-25	2008-02-25	Icos Corp	Inhibitors of human phosphatidyl-inositol 3-kinase delta
CN100345830C (zh) *	2000-04-27	2007-10-31	安斯泰来制药有限公司	稠合杂芳基衍生物

2003
- 2003-09-18 JP JP2004538935A patent/JP4790266B2/ja not_active Expired - Lifetime
- 2003-09-18 AT AT08075839T patent/ATE511510T1/de active
- 2003-09-18 BR BRPI0314830A patent/BRPI0314830B8/pt active IP Right Grant
- 2003-09-18 DE DE60324296T patent/DE60324296D1/de not_active Expired - Lifetime
- 2003-09-18 PT PT08075839T patent/PT2042504E/pt unknown
- 2003-09-18 SI SI200331490T patent/SI1549652T1/sl unknown
- 2003-09-18 SI SI200332036T patent/SI2042504T1/sl unknown
- 2003-09-18 WO PCT/EP2003/010377 patent/WO2004029055A1/en active Application Filing
- 2003-09-18 PT PT03788908T patent/PT1549652E/pt unknown
- 2003-09-18 DK DK03788908T patent/DK1549652T3/da active
- 2003-09-18 EP EP03788908A patent/EP1549652B1/en not_active Expired - Lifetime
- 2003-09-18 US US10/527,376 patent/US7511041B2/en active Active
- 2003-09-18 AU AU2003293310A patent/AU2003293310B2/en not_active Expired
- 2003-09-18 PL PL375935A patent/PL226562B1/pl unknown
- 2003-09-18 NZ NZ539062A patent/NZ539062A/en not_active IP Right Cessation
- 2003-09-18 ES ES08075839T patent/ES2367141T3/es not_active Expired - Lifetime
- 2003-09-18 ES ES03788908T patent/ES2312843T3/es not_active Expired - Lifetime
- 2003-09-18 CA CA2499134A patent/CA2499134C/en not_active Expired - Lifetime
- 2003-09-18 MX MXPA05001808A patent/MXPA05001808A/es active IP Right Grant
- 2003-09-18 CN CNB038233673A patent/CN100384846C/zh not_active Expired - Lifetime
- 2003-09-18 EP EP08075839A patent/EP2042504B1/en not_active Expired - Lifetime
- 2003-09-18 AT AT03788908T patent/ATE411996T1/de active
- 2003-09-18 KR KR1020057005434A patent/KR101059652B1/ko active IP Right Grant
- 2003-09-18 UA UAA200504176A patent/UA82205C2/uk unknown
- 2003-09-18 DK DK08075839.4T patent/DK2042504T3/da active
- 2003-09-18 RU RU2005113165/04A patent/RU2326881C9/ru active
- 2003-09-29 UY UY28001A patent/UY28001A1/es active IP Right Grant
- 2003-09-29 TW TW092126767A patent/TWI327570B/zh not_active IP Right Cessation
- 2003-09-29 PE PE2003000986A patent/PE20050089A1/es active IP Right Grant
- 2003-09-29 AR ARP030103542A patent/AR041426A1/es active IP Right Grant
- 2003-09-29 MY MYPI20033701A patent/MY140756A/en unknown
2005
- 2005-02-14 IL IL166855A patent/IL166855A/en active IP Right Grant
- 2005-04-25 ZA ZA200503306A patent/ZA200503306B/en unknown
- 2005-04-27 HR HRP20050375AA patent/HRP20050375B1/hr not_active IP Right Cessation
- 2005-04-27 NO NO20052076A patent/NO331457B1/no not_active IP Right Cessation
- 2005-04-28 EC EC2005005768A patent/ECSP055768A/es unknown
- 2005-04-29 MA MA28247A patent/MA27483A1/fr unknown
2006
- 2006-04-19 HK HK06104675.8A patent/HK1084393A1/xx not_active IP Right Cessation
2009
- 2009-01-09 CY CY20091100017T patent/CY1109790T1/el unknown
- 2009-03-30 US US12/414,257 patent/US8129386B2/en not_active Expired - Lifetime
- 2009-07-01 AR ARP090102458A patent/AR072458A2/es not_active Application Discontinuation
2011
- 2011-02-07 EC EC2011005768A patent/ECSP11005768A/es unknown
- 2011-08-10 CY CY20111100771T patent/CY1112174T1/el unknown
2013
- 2013-12-04 HR HRP20131159A patent/HRP20131159B1/hr not_active IP Right Cessation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3644354A (en) *	1968-09-16	1972-02-22	Sandoz Ag	5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
CN1089266A (zh) *	1993-01-02	1994-07-13	陈基旺	3-取代甲基-2，3-二氢咪唑并[1，2-c]喹唑啉衍生物，其制备与用途
US5932584A (en) *	1997-05-06	1999-08-03	National Science Council	Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A Specific Inhibitor Phosphatidylinositol3-Kinase,2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one(LY294002). Chris J.Vlahos ET AL.The Journal of Biological Chemistry,Vol.269 No.7. 1994
A Specific Inhibitor Phosphatidylinositol3-Kinase,2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one(LY294002). Chris J.Vlahos ET AL.The Journal of Biological Chemistry,Vol.269 No.7. 1994 *
Wortmannin as a unique probe for an intracellularsignallingprotein,phosphoinositide 3-kinase. Michio Ui ET AL.Trends in Biochemical Sciences,Vol.20 No.8. 1995
Wortmannin as a unique probe for an intracellularsignallingprotein,phosphoinositide 3-kinase. Michio Ui ET AL.Trends in Biochemical Sciences,Vol.20 No.8. 1995 *

Also Published As

Publication number	Publication date
TW200413379A (en)	2004-08-01
ES2367141T3 (es)	2011-10-28
BR0314830A (pt)	2005-08-16
PE20050089A1 (es)	2005-04-20
JP2006508063A (ja)	2006-03-09
MA27483A1 (fr)	2005-08-01
US7511041B2 (en)	2009-03-31
IL166855A (en)	2014-05-28
EP1549652B1 (en)	2008-10-22
DK2042504T3 (da)	2011-09-19
US20060128732A1 (en)	2006-06-15
MXPA05001808A (es)	2005-08-16
CN1688582A (zh)	2005-10-26
BRPI0314830B1 (pt)	2018-03-27
US20090270388A1 (en)	2009-10-29
RU2326881C2 (ru)	2008-06-20
DK1549652T3 (da)	2009-02-23
TWI327570B (en)	2010-07-21
SI1549652T1 (sl)	2009-04-30
UA82205C2 (en)	2008-03-25
ECSP055768A (es)	2005-08-11
CA2499134C (en)	2011-12-20
EP1549652A1 (en)	2005-07-06
HRP20131159A2 (hr)	2014-05-23
DE60324296D1 (de)	2008-12-04
KR20050067404A (ko)	2005-07-01
RU2326881C9 (ru)	2009-04-10
ATE411996T1 (de)	2008-11-15
JP4790266B2 (ja)	2011-10-12
WO2004029055A1 (en)	2004-04-08
CY1112174T1 (el)	2015-12-09
MY140756A (en)	2010-01-15
AU2003293310A1 (en)	2004-04-19
US8129386B2 (en)	2012-03-06
HRP20131159B1 (hr)	2019-11-01
PT1549652E (pt)	2008-12-15
AU2003293310B2 (en)	2010-04-01
PT2042504E (pt)	2011-09-07
RU2005113165A (ru)	2005-10-10
PL375935A1 (en)	2005-12-12
EP2042504B1 (en)	2011-06-01
UY28001A1 (es)	2004-04-30
CY1109790T1 (el)	2014-09-10
HK1084393A1 (en)	2006-07-28
NZ539062A (en)	2007-05-31
BRPI0314830B8 (pt)	2021-05-25
ECSP11005768A (es)	2011-03-31
AR041426A1 (es)	2005-05-18
KR101059652B1 (ko)	2011-08-25
HRP20050375A2 (en)	2006-05-31
ZA200503306B (en)	2006-07-26
SI2042504T1 (sl)	2011-10-28
EP2042504A1 (en)	2009-04-01
CA2499134A1 (en)	2004-04-08
ATE511510T1 (de)	2011-06-15
NO331457B1 (no)	2012-01-09
PL226562B1 (pl)	2017-08-31
HRP20050375B1 (hr)	2014-03-14
AR072458A2 (es)	2010-09-01
NO20052076L (no)	2005-04-27
ES2312843T3 (es)	2009-03-01

Legal Events

Date	Code	Title	Description
2005-10-26	C06	Publication
2005-10-26	PB01	Publication
2005-12-21	C10	Entry into substantive examination
2005-12-21	SE01	Entry into force of request for substantive examination
2006-07-28	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1084393 Country of ref document: HK
2008-04-30	C14	Grant of patent or utility model
2008-04-30	GR01	Patent grant
2009-03-27	REG	Reference to a national code	Ref country code: HK Ref legal event code: GR Ref document number: 1084393 Country of ref document: HK
2010-05-26	ASS	Succession or assignment of patent right	Owner name: BAYER SCHERING PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BAYER PHARMACEUTICAL CO., LTD. Effective date: 20100420
2010-05-26	C41	Transfer of patent application or patent right or utility model
2010-05-26	COR	Change of bibliographic data	Free format text: CORRECT: ADDRESS; FROM: CONNECTICUT STATE, U.S.A TO: BERLIN, GERMANY
2010-05-26	TR01	Transfer of patent right	Effective date of registration: 20100420 Address after: Berlin Patentee after: BAYER SCHERING PHARMA AG Address before: American Connecticut Patentee before: Bayer Pharmaceuticals Corp.
2013-04-10	ASS	Succession or assignment of patent right	Owner name: BAYER INTELLECTUAL PROPERTY GMBH Free format text: FORMER OWNER: BAYER PHARMACEUTICALS AG Effective date: 20130322
2013-04-10	C41	Transfer of patent application or patent right or utility model
2013-04-10	C56	Change in the name or address of the patentee	Owner name: BAYER PHARMACEUTICALS AG Free format text: FORMER NAME: BAYER SCHERING PHARMA AG
2013-04-10	CP01	Change in the name or title of a patent holder	Address after: Berlin Patentee after: BAYER PHARMA AG Address before: Berlin Patentee before: Bayer Schering Pharma AG
2013-04-10	TR01	Transfer of patent right	Effective date of registration: 20130322 Address after: German Monheim Patentee after: BAYER INTELLECTUAL PROPERTY GmbH Address before: Berlin Patentee before: BAYER PHARMA AG
2023-10-10	CX01	Expiry of patent term
2023-10-10	CX01	Expiry of patent term	Granted publication date: 20080430

Publication	Publication Date	Title
CN100384846C (zh)	2008-04-30	稠合吡咯-嘧啶衍生物
CN102695710B (zh)	2015-08-19	三环吡唑胺衍生物
CA2996318C (en)	2023-10-10	Heteroaryl compounds as irak inhibitors and uses thereof
JP5529852B2 (ja)	2014-06-25	置換アミド、その製造法及びＢｔｋインヒビターとしての使用
ES2742409T3 (es)	2020-02-14	Inhibidores de quinasa de pirazolilquinoxalina
KR101444481B1 (ko)	2014-09-24	치환된 아미드, 그의 제조 방법, 및 그의 사용 방법
RU2559895C2 (ru)	2015-08-20	Азотосодержащие производные гетероарилов
CA2714888C (en)	2017-03-14	Pyrimidyl cyclopentanes as akt protein kinase inhibitors
CN103998042B (zh)	2016-12-28	Pi3k的活性或功能的抑制剂的应用
EP1620094A2 (en)	2006-02-01	Novel chemical compounds
CN101952287B (zh)	2013-11-27	蛋白激酶抑制剂及其应用
CN1988934B (zh)	2011-01-05	四氢吡啶并噻吩化合物
EA031971B1 (ru)	2019-03-29	Гетероциклические амины в качестве ингибиторов киназы
CN105899505A (zh)	2016-08-24	用于治疗自身免疫病症的吡唑
CN103635473A (zh)	2014-03-12	二螺吡咯烷衍生物
CN103874699A (zh)	2014-06-18	吡唑并[4,3-c]吡啶衍生物作为激酶抑制剂
JP2003501429A (ja)	2003-01-14	ベンゾチアジノンおよびベンゾオキサジノン化合物
CN105452257A (zh)	2016-03-30	新型稠合嘧啶化合物或其盐
CN101511842A (zh)	2009-08-19	作为akt蛋白激酶抑制剂的二氢呋喃并嘧啶
CN108026080A (zh)	2018-05-11	吡唑基取代的杂芳基化合物及其作为药物的用途
CN103282363B (zh)	2016-08-10	咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
US20150307491A1 (en)	2015-10-29	Substituted pyridopyrazines as syk inhibitors
CN101827820A (zh)	2010-09-08	氨基吡唑酰胺衍生物
CN101142215A (zh)	2008-03-12	卤代芳基取代的氨基嘌呤、其组合物及其治疗方法
CN101006055B (zh)	2011-06-22	作为酪蛋白激酶Iε抑制剂的3-取代的-5-和6-氨基烷基吲哚-2-羧酸酰胺以及相关类似物